PURPOSE OF REVIEW: Inflammatory bowel diseases (IBDs) are disorders of multifactorial cause that present as a multitude of phenotypes, clinical behaviours and severity. Crohn's disease and ulcerative colitis are considered as the two extremes of what is believed to be a spectrum of chronic gut inflammation and this separation is still the first classification used when confronted with an IBD patient. An accurate classification within IBD has several benefits, with respect to patient counselling, assessing risk for disease progression, and particularly with respect to choosing the most appropriate therapy for an individual patient. Basic scientists on the other hand prefer classifications that would allow to better understand the pathophysiology of the different manifestations of Crohn's disease and ulcerative colitis. RECENT FINDINGS: Attempts to reclassify IBD based on recent genetic, serologic or immunologic findings have been made. Most, however, have not been translated to daily practice and need confirmation first. SUMMARY: Clinicians should apply a systematic approach to their patients by using existing phenotypic classifications such as Montreal or Paris. They should further recognize clinical and endoscopic features of bad outcome such as perianal disease, deep ulcers on colonoscopy and extensive small bowel involvement.
PURPOSE OF REVIEW: Inflammatory bowel diseases (IBDs) are disorders of multifactorial cause that present as a multitude of phenotypes, clinical behaviours and severity. Crohn's disease and ulcerative colitis are considered as the two extremes of what is believed to be a spectrum of chronic gut inflammation and this separation is still the first classification used when confronted with an IBD patient. An accurate classification within IBD has several benefits, with respect to patient counselling, assessing risk for disease progression, and particularly with respect to choosing the most appropriate therapy for an individual patient. Basic scientists on the other hand prefer classifications that would allow to better understand the pathophysiology of the different manifestations of Crohn's disease and ulcerative colitis. RECENT FINDINGS: Attempts to reclassify IBD based on recent genetic, serologic or immunologic findings have been made. Most, however, have not been translated to daily practice and need confirmation first. SUMMARY: Clinicians should apply a systematic approach to their patients by using existing phenotypic classifications such as Montreal or Paris. They should further recognize clinical and endoscopic features of bad outcome such as perianal disease, deep ulcers on colonoscopy and extensive small bowel involvement.
Authors: Jennifer L Bennett; Christina Y Ha; Jonathan E Efron; Susan L Gearhart; Mark G Lazarev; Elizabeth C Wick Journal: World J Gastroenterol Date: 2015-01-28 Impact factor: 5.742
Authors: Saurabh Kedia; Raju Sharma; Govind K Makharia; Vineet Ahuja; Devendra Desai; Devasenathipathy Kandasamy; Anu Eapen; Karthik Ganesan; Uday C Ghoshal; Naveen Kalra; D Karthikeyan; Kumble Seetharama Madhusudhan; Mathew Philip; Amarender Singh Puri; Sunil Puri; Saroj K Sinha; Rupa Banerjee; Shobna Bhatia; Naresh Bhat; Sunil Dadhich; G K Dhali; B D Goswami; S K Issar; V Jayanthi; S P Misra; Sandeep Nijhawan; Pankaj Puri; Avik Sarkar; S P Singh; Anshu Srivastava; Philip Abraham; B S Ramakrishna Journal: Indian J Gastroenterol Date: 2018-01-06
Authors: Kristen L Reti; Lisa D Tymensen; Shevaun P Davis; Matthias W Amrein; Andre G Buret Journal: Infect Immun Date: 2015-09-14 Impact factor: 3.441
Authors: Melissa A Fernandes; Sofia G Verstraete; Elizabeth A Garnett; Melvin B Heyman Journal: J Pediatr Gastroenterol Nutr Date: 2016-02 Impact factor: 2.839
Authors: Maria E C Bruno; Eric W Rogier; Razvan I Arsenescu; Deborah R Flomenhoft; Cathryn J Kurkjian; Gavin I Ellis; Charlotte S Kaetzel Journal: Dig Dis Sci Date: 2015-05-09 Impact factor: 3.199